Premium
The Cardiac Insufficiency Talinolol Study (CITAS) study design
Author(s) -
Campeanu Alexandru
Publication year - 2001
Publication title -
european journal of heart failure
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.149
H-Index - 133
eISSN - 1879-0844
pISSN - 1388-9842
DOI - 10.1016/s1388-9842(01)00133-7
Subject(s) - medicine , heart failure , cardiology , intensive care medicine
Beta‐blockers without partial agonist activity are now considered to be strategic therapy for patients with chronic heart failure, but many issues remain to be clarified. The objective of the double‐blind, randomized, placebo‐controlled cardiac insufficiency talinolol study (CITAS) is to assess efficacy and safety of talinolol — a selective beta‐1 adrenoreceptor blocker — in patients with ischemic and non‐ischemic heart failure. The primary end‐point refers to the influence of talinolol on exercise capacity, evaluated by 6‐min walking‐test. Secondary end‐points consist of left ventricular function, cardiovascular and all‐cause mortality, hospitalizations, quality of life, combined clinical end‐points and adverse events. There were enrolled 294 patients with stable heart failure in NYHA class II–IV, LVEF < 40%, receiving diuretics, ACE‐inhibitors and optionally nitrates and digoxin. Talinolol was titrated up to 100 mg/day (one arm) or to 150 mg/d (the other arm), starting with 12.5 mg daily. Enrollment began in November 1997 and the last visit will be in December 2000.